Issue link: https://www.e-digitaleditions.com/i/1544305
36 April 2026 Inhalation The transition to low-GWP propellants for MDIs Orbia Fluor & Energy Materials' Pharma business unit is advancing the transition to sustainable inha- lation therapies through Zephex ® 152a, its low-GWP medical propellant designed for use in metered dose inhalers (MDIs). With significantly lower global warming potential compared to traditional propel- lants, Zephex 152a can enable pharmaceutical com- panies to reduce the carbon footprint of their MDIs while maintaining established inhaler performance and patient experience. Orbia is investing in large- scale manufacturing capacity and supply reliabil- ity to support global demand as respiratory markets move toward environmentally responsible solutions. Backed by over 30 years of experience, robust qual- ity systems and regulatory alignment, Zephex 152a is positioned to help the industry meet sustainability goals without compromising therapeutic delivery. Orbia United Kingdom www.orbia.com Fast to clinic formulation platform for DPI products Intertek's new partnership with CrystecPharma sup- ports global clients in accelerating development time- lines for inhaled medicines, particularly dry powder inhalers (DPIs). A "fast to clinic" platform can enable rapid product development from the initial formu- lation concept to GMP clinical manufacturing in less than half the time typically required. is highly agile capability can allow clients aiming to formulate new small or large (biologic) molecules, or repurpose existing active pharmaceutical ingredients, to benefit from technology that enables new forms of molecules and novel particles to be manufactured in ways that greatly enhance their therapeutic performance. Intertek Pharmaceutical Services UK: +44 1763 261648 bd.melbourn@intertek.com www.intertek.com Respiratory drug product development software Fusion Process Development (FPD) for respiratory drug product R&D is the perfect companion mod- ule to Fusion Inhaler Testing (FIT) for QC. FPD has automated Design of Experiments (DoE) and data modeling for formulation and process R&D. FPD enables you to create companion testing designs for your formulation and device design studies with full bi-directional Chromatography Data Software (CDS) testing automation. Automated CDS testing and data retrieval includes handling of complex data from cas- cade impaction testing and dissolution testing. And FPD operates under full regulatory compliance to maintain data integrity. S-Matrix ® US: +1 707 441-0406 sales@smatrix.com www.smatrix.com Integrated solutions for pulmonary and nasal delivery With 30+ years' experience in pulmonary and nasal delivery, Catalent offers integrated solutions with clinical- to commercial-scale development and man- ufacturing capabilities for spray-dried or micronized dry powders for inhalation, capsules for inhalation and unit-dose, bi-dose and multi-dose nasal liquid and powder products, including sterile vials for neb- ulization of small molecules and biopharmaceuticals. In addition, Catalent provides comprehensive ana- lytical and clinical supply services to support your molecule from development through product launch and beyond. With state-of-the-art facilities in Boston, Massachusetts and Morrisville, North Carolina, US, Catalent can handle the most complex projects and help bring your inhaled therapy to market, faster. Catalent US: +1 888 SOLUTION (765-8846) solutions@catalent.com www.catalent.com

